vanessapu, quite a coincidence that you ask that question.
I would say no. BUT I would immediately add that I have been thinking at times that some clinical trials might have Bavituximab molecule copies in their clinical trials.
Since we have seen several companies the offer bavituximab (under the statement that it might be a protected substance but that the buyer must make the needed arrangements) I think it must not be very difficult for a BP to copy it also. Suppose that during the dose switching some Bavituximab disappeared (say to be able to analyse it) then a copy could be in circulation.
One could then get an advantage in mixing Bavi in the own drug under investigation and I guess no one would easily find out if you don't specifically look for it. All other effects (eg/ MDSCs increments) would then be attributed to the new drug.
News 
Market Data 
Discover 
